3.7298

3.72% -0.1702

Verastem Inc (VSTM)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Verastem Inc stock is traded at $3.7298, with a volume of 447.45K. It is down -3.72% in the last 24 hours and up +30.84% over the past month. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Previous Close:

$3.90

Open:

$3.85

24h Volume:

447.45K

Relative Volume:

0.64

Market Cap:

$156.95M

Revenue:

$3.64M

Net Income/Loss:

$-87.37M

P/E Ratio:

-0.8535

EPS:

-4.37

Net Cash Flow:

$-86.46M

1W Performance:

+4.31%

1M Performance:

+30.84%

6M Performance:

-65.55%

1Y Performance:

-45.18%

1-Day Range:

$3.6626

$3.9099

1-Week Range:

$3.54

$4.00

52-Week Range:

$2.10

$14.22

Verastem Inc Stock (VSTM) Company Profile

Name

Verastem Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(781) 292-4200

Address

117 KENDRICK STREET, NEEDHAM, MA

Employee

Twitter

@VerastemOncolog

Next Earnings Date

2024-11-06

Latest SEC Filings

VSTM's Discussions on Twitter

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-07-22	Resumed	Alliance Global Partners	Buy
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight
Apr-14-22	Initiated	RBC Capital Mkts	Outperform
Mar-09-22	Initiated	Truist	Buy
Jul-01-21	Initiated	Alliance Global Partners	Buy
May-24-21	Upgrade	BTIG Research	Neutral → Buy
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy
May-02-18	Initiated	Seaport Global Securities	Buy
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy
Sep-07-17	Reiterated	H.C. Wainwright	Buy
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy
Sep-29-15	Downgrade	Cantor Fitzgerald	Buy → Hold
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-28-15	Downgrade	Mizuho	Buy → Neutral
Sep-28-15	Downgrade	ROTH Capital	Buy → Neutral
Sep-09-15	Initiated	Raymond James	Strong Buy
May-12-15	Reiterated	UBS	Buy
Apr-08-15	Initiated	H.C. Wainwright	Buy
Jan-23-15	Reiterated	ROTH Capital	Buy
Jul-08-14	Resumed	Oppenheimer	Perform
Feb-11-14	Initiated	Mizuho	Buy

View All

Verastem Inc Stock (VSTM) Latest News

Nov 04, 2024

Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com

Nov 04, 2024

Nov 02, 2024

Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times

Nov 02, 2024

Nov 01, 2024

Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance

Nov 01, 2024

Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024

Oct 31, 2024

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan

Oct 31, 2024

Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace

Oct 31, 2024

Oct 30, 2024

SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Oct 30, 2024

Oct 24, 2024

Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India

Oct 24, 2024

Oct 21, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 21, 2024

Oct 18, 2024

Verastem preps an NDA as the stock struggles - BioWorld Online

Oct 18, 2024

Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 18, 2024

Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders

Oct 18, 2024

Oct 17, 2024

Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK

Oct 17, 2024

Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks

Oct 17, 2024

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan

Oct 17, 2024

Oct 15, 2024

This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News

Oct 15, 2024

Oct 14, 2024